趋化因子SD-1及其受体CXCR4在卵巢癌中的研究进展

基质细胞衍生因子-1(Stromal cell derived factor-1,SDF-1)是CXC趋化因子家族的重要成员,系统命名为CXCL12,能与它的唯一受体CXC趋化因子受体-4(CXC chemokine receptor-4,CXCR4)形成CXCL12-CXCR4生物学轴,CXCL12-CXCR4生物学轴在肿瘤生长、侵袭、转移过程中发生重要作用。到目前为止,已发现CXCL12-CXCR4在卵巢癌、胰腺癌、肝癌等多种肿瘤组织中表达。然而,国内目前还没有关于CXCL12-CXCR4与卵巢癌关系的相关综述,本文将从趋化因子CXCL12及其受体CXCR4,CXCL12/CXCR4轴与卵巢癌细胞系实验研究,CXCL12-CXCR4轴与卵巢癌的临床研究,CXCL12/CXCR4与卵巢癌预后,CXCL12/CXCR4与卵巢癌治疗展望等五个方面对CXCL12-CXCR4生物轴与卵巢癌的关系,及其在卵巢癌治疗中的应用展开综述。

Progress of Chemokine SD-1 and Its Receptor CXCR4 in Ovarian Cancer

SDF-1(Stromal cell derived factor-1), system named as CXCL12, is an important member of CXC chemokine family, which could form CXCL12-CXCR4 biological axis with its only receptor CXCR4 (CXC chemokine receptor 4). CXCL12-CXCR4 biological axis played an important role in tumor growth, invasion and metastasis. So far, it was found that CXCL12-CXCR4 was expressed in various tumor tissues, such as ovarian cancer, pancreatic cancer, and liver cancer. However, there is no domestic reviews on the relationship between CXCL12-CXCR4 and ovarian cancer. In this article, the relationship of CXCL12-CXCR4 biological axis and ovarian cancer, and its application in the treatment of ovarian cancer were reviewed from the following five aspects: CXCL12 and CXCR4; the role ofCXCL12/CXCR4 axis in the experimental study of ovarian cancer cell lines; CXCL12/CXCR4 axis and clinical research on ovarian cancer; role of CXCL12/CXCR4 in ovarian cancer prognosis; and role of CXCL12/CXCR4 in ovarian cancer treatment.